***Gene augmentation therapy for EYS- or PCARE-associated RP***

Homozygous or compound heterozygous mutations in *EYS* or *PCARE* account for 5-10% and 1-2% of all autosomal recessive RP cases, respectively. This project focuses on understanding the role of the EYS and PCARE protein in the retina, as well as the design of gene augmentation strategies to treat these genetic subtypes of IRD. We have employed a variety of molecular and cell biological techniques, and mutant zebrafish models to gain insight into the physiological role of these two proteins. Current work includes the development and optimization of therapeutic vectors that aim to restore correct protein synthesis and cellular function.

**People involved:**

* R. (Ronald) Roepman, principal investigator
* A. (Alejandro) Garanto, assistant professor
* I.J.M. (Ideke) Lamers, post-doctoral researcher
* A. (Tess) Afanasyeva, PhD candidate  
    
  **Funding:**
* Algemene Nederlandse Vereniging ter Voorkoming van Blindheid
* Gelderse Blindenstichting
* Landelijke Stichting voor Blinden en Slechtzienden
* Macula Fonds
* Oogfonds
* Rotterdamse Stichting Blindenbelangen
* Stichting Blindenhulp
* Stichting Blinden-Penning
* Stichting Dowilvo
* Stichting tot Verbetering van het Lot der Blinden